US 11,903,953 B2
Remdesivir treatment methods
Tomas Cihlar, Burlingame, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Mar. 30, 2023, as Appl. No. 18/128,850.
Application 18/128,850 is a continuation of application No. 17/333,389, filed on May 28, 2021.
Claims priority of provisional application 63/032,321, filed on May 29, 2020.
Prior Publication US 2023/0233587 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/675 (2013.01) [A61P 31/14 (2018.01)] 15 Claims
 
1. A method of treating a viral infection in a human in need thereof,
the method comprising administering to the human an antiviral compound;
wherein
the human has not been administered chloroquine, or an analog or salt thereof;
the antiviral compound is converted to a compound of Formula II, or a pharmaceutically acceptable salt thereof, upon administration to the human;

OG Complex Work Unit Chemistry
and
the concentration of the compound of Formula II in plasma or blood is optimized in the absence of chloroquine, or an analog or salt thereof.